These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 21300764)

  • 1. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
    Burnette BC; Liang H; Lee Y; Chlewicki L; Khodarev NN; Weichselbaum RR; Fu YX; Auh SL
    Cancer Res; 2011 Apr; 71(7):2488-96. PubMed ID: 21300764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
    Chen J; Cao Y; Markelc B; Kaeppler J; Vermeer JA; Muschel RJ
    J Clin Invest; 2019 Oct; 129(10):4224-4238. PubMed ID: 31483286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
    Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
    Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.
    Lim JY; Gerber SA; Murphy SP; Lord EM
    Cancer Immunol Immunother; 2014 Mar; 63(3):259-71. PubMed ID: 24357146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
    Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
    Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
    Fuertes MB; Kacha AK; Kline J; Woo SR; Kranz DM; Murphy KM; Gajewski TF
    J Exp Med; 2011 Sep; 208(10):2005-16. PubMed ID: 21930765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
    Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity.
    Zhang F; Manna S; Pop LM; Chen ZJ; Fu YX; Hannan R
    Semin Radiat Oncol; 2020 Apr; 30(2):129-138. PubMed ID: 32381292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.
    Simmons DP; Canaday DH; Liu Y; Li Q; Huang A; Boom WH; Harding CV
    J Immunol; 2010 Aug; 185(4):2405-15. PubMed ID: 20660347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment.
    Gangaplara A; Martens C; Dahlstrom E; Metidji A; Gokhale AS; Glass DD; Lopez-Ocasio M; Baur R; Kanakabandi K; Porcella SF; Shevach EM
    PLoS Pathog; 2018 Apr; 14(4):e1006985. PubMed ID: 29672594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myd88 Initiates Early Innate Immune Responses and Promotes CD4 T Cells during Coronavirus Encephalomyelitis.
    Butchi N; Kapil P; Puntambekar S; Stohlman SA; Hinton DR; Bergmann CC
    J Virol; 2015 Sep; 89(18):9299-312. PubMed ID: 26136579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
    Diamond MS; Kinder M; Matsushita H; Mashayekhi M; Dunn GP; Archambault JM; Lee H; Arthur CD; White JM; Kalinke U; Murphy KM; Schreiber RD
    J Exp Med; 2011 Sep; 208(10):1989-2003. PubMed ID: 21930769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity.
    Liang Y; Hannan R; Fu YX
    Clin Cancer Res; 2021 Jul; 27(14):3818-3824. PubMed ID: 33692027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor.
    Kono DH; Baccala R; Theofilopoulos AN
    Autoimmunity; 2003 Dec; 36(8):503-10. PubMed ID: 14984027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells.
    Bochtler P; Kröger A; Schirmbeck R; Reimann J
    J Immunol; 2008 Aug; 181(3):1633-43. PubMed ID: 18641299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRF-7 is the master regulator of type-I interferon-dependent immune responses.
    Honda K; Yanai H; Negishi H; Asagiri M; Sato M; Mizutani T; Shimada N; Ohba Y; Takaoka A; Yoshida N; Taniguchi T
    Nature; 2005 Apr; 434(7034):772-7. PubMed ID: 15800576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.
    Van der Jeught K; Joe PT; Bialkowski L; Heirman C; Daszkiewicz L; Liechtenstein T; Escors D; Thielemans K; Breckpot K
    Oncotarget; 2014 Oct; 5(20):10100-13. PubMed ID: 25338019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autocrine Type I IFN Signaling in Dendritic Cells Stimulated with Fungal β-Glucans or Lipopolysaccharide Promotes CD8 T Cell Activation.
    Hassanzadeh-Kiabi N; Yáñez A; Dang I; Martins GA; Underhill DM; Goodridge HS
    J Immunol; 2017 Jan; 198(1):375-382. PubMed ID: 27872213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.